Premium
P2‐329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI
Author(s) -
Chen Qin,
Boeve Bradley F.,
Schwarz Christopher G.,
Reid Robert I.,
Tosakulwong Nirubol,
Lesnick Timothy G.,
Bove Jessica,
Brannelly Patrick,
Brushaber Danielle,
Coppola Giovanni,
Dheel Christina,
Dickerson Brad C.,
Dickinson Susan,
Faber Kelley,
Fields Julie A.,
Fong Jamie,
Foroud Tatiana M.,
Forsberg Leah K.,
Gavrilova Ralitza H.,
Gearhart Debra,
Ghoshal Nupur,
Goldman Jill,
Graff-Radford Jonathan,
Graff-Radford Neill R.,
Grossman Murray,
Haley Dana,
Heuer Hilary W.,
Robin Hsiung Ging-Yuek,
Huey Edward D.,
Irwin David,
Jack Clifford R.,
Jones David T.,
Jones Lynne,
Karydas Anna M.,
Knopman David S.,
Kornak John,
Kramer Joel H.,
Kremers Walter K.,
Kukull Walter A.,
Lapid Maria I.,
Lucente Diane E.,
Lungu Codrin,
Mackenzie Ian R.,
Manoochehri Masood,
McGinnis Scott,
Miller Bruce L.,
Pearlman Rodney,
Petrucelli Leonard,
Potter Madeline,
Rademakers Rosa,
Ramos Eliana Marisa,
Rankin Katherine,
Rascovsky Katya,
Sengdy Pheth,
Shaw Leslie M.,
Syrjanen Jeremy,
Tatton Nadine,
Taylor Joanne,
Toga Arthur W.,
Trojanowski John Q.,
Weintraub Sandra,
Wong Bonnie,
Boxer Adam L.,
Rosen Howard J.,
Wszolek Zbigniew,
Kantarci Kejal
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2736
Subject(s) - asymptomatic , asymptomatic carrier , white matter , fractional anisotropy , diffusion mri , frontotemporal lobar degeneration , medicine , frontotemporal dementia , pathology , dementia , magnetic resonance imaging , radiology , disease
of amyloid-b, tau and CVD on clinical symptoms and outcome in DLB. Methods: One-hundred people with mild to moderate probable DLB (age 50+) will be invited to complete comprehensive clinical and cognitive assessments including (including MMSE, ACE-III, MoCA, CDR, NPI, GDS), function / activities of daily living, health related quality of life and carer burden. Scales targeting DLB-specific clinical features (such as fluctuations and REMsleep behaviour disorder) will also be collected including the Clinician Assessment of Fluctuation Scale, Mayo Fluctuation Scale, and Mayo Sleep Questionnaire. Biomarker protocols incorporate blood sampling (including ApoE genotyping and systemic inflammatory markers), molecular imaging (amyloid[F-NAV 4694], tau [FMK6240], VMAT2 [F-AV133] PET scans), 3T MRI (including high resolution structural imaging, diffusion tensor imaging, and quantitative susceptibility mapping), and CSF collection for amyloidb, tau and a-synuclein. Clinical assessments are completed 6 monthly and imaging 18 monthly. Participants are also invited to register for post-mortem brain tissue donation. Results: Twelve participants with probable DLB have been recruited to date (mean age 72.4 years, range 64-82, 80% male). All participants have mild to moderate cognitive impairment (mean MMSE 25, range 17-29). Half of the participants are amyloid-b positive and 40% are Tau-positive on PET imaging. Study procedure tolerability has been excellent with no adverse events reported. Further biomarker results and associations with baseline cognitive performance will be presented at AAIC. Conclusions: Determining the influence of multimorbidity is key to the development of effective symptomatic and disease modifying treatment strategies in DLB. This study supports the feasibility of intensive, longitudinal biomarker studies in dementia with Lewy bodies in the Australian Setting.